Vivacta has established a revenue-generating collaborative model in which the company’s technology platform operates as a new product development engine for diagnostic tests using whole blood or other sample matrices.

Collaborations may focus on developing assays for the identification, diagnosis or monitoring of disease or for other applications including as companion diagnostics, for drug or biomarker monitoring and for the monitoring of therapeutic effectiveness such as the detection of anti-drug antibodies. Collaborations may also extend to development of assays allowing the determination of vaccination status, as well as other personalised medicine applications. Diagnostic products can be established for the detection and quantification of proteins, antibodies and small molecules, although other analyte types are also possible.

Vivacta provides partners with comprehensive licensing and technology transfer packages to support clinical trials, regulatory filings, commercial manufacturing and marketing.

Partnerships may be with major diagnostics or pharmaceutical companies wishing to develop point-of-care assays for early market entry and may involve development of assays for particular medical environments including hospital-based critical care or in the establishment of IT-connected but decentralised healthcare networks in which diagnostic capability is provided at the point of need, remote from the central hospital laboratory or “healthcare hub”.

As well as collaborating on analytes proposed by partners, Vivacta will in due course establish strategic partnerships for the further development and commercialisation of its in-house projects including the TSH and cardiac programmes.